Galderma's CEO Flemming Ørnskov revealed that the rising use of GLP-1 weight-loss medications like Ozempic and Wegovy is driving strong growth in the company's aesthetics portfolio, including fillers and anti-wrinkle treatments. About 10% of U.S. adults now use these drugs, creating demand for products that address facial sagging linked to significant weight loss, a condition sometimes called "Ozempic face." Galderma reported nearly 25% sales growth year-on-year at constant currencies, with U.S. sales growing 32%, outpacing other regions. This trend presents a significant but early-stage opportunity for the company in the aesthetics market.
FREELANDER 8 has started mass production at the Chery Jaguar Land Rover Changshu Manufacturing Base in China, a facility with over $3.1 billion invested, including $440 million for NEV upgrades. This plant combines British premium manufacturing with ...
A potential Bitcoin fork linked to the BIP-110 proposal could create duplicate balances on two chains, tempting holders to sell the new forked coins. However, selling these coins risks a replay attack, where the same transaction is copied on the main...
Canada's labor market surged in July with 75,000 new jobs, far exceeding expectations, while US payrolls declined by 23,000. This divergence may influence central bank policies, with the Bank of Canada likely to hold rates steady and the US Federal R...
Trump Media and Technology Group has abandoned its plan to create a publicly traded company to accumulate Cronos (CRO) tokens due to challenging market conditions and changing priorities. The company is also scaling back its partnership with Crypto.c...
Cardano (ADA) is showing strong recovery momentum, pushing toward the key $0.20 resistance level. Despite a recent minor pullback, ADA remains above its 20-day and 50-day moving averages, signaling ongoing bullish strength. The critical level to watc...
